Table of Contents

Research Articles

• Research Articles

  A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2⁺ Metastatic Breast Cancer

  Gang Chen, Richa Gupta, Silvia Petrik, Marina Laiko, James M. Leatherman, Justin M. Asquith, Maithili M. Daphtary, Elizabeth Garrett-Mayer, Nancy E. Davidson, Kellie Hirt, Maureen Berg, Jennifer N. Uram, Tianna Dauses, John Fetting, Elizabeth M. Duus, Saadet Atay-Rosenthal, Xiaobu Ye, Antonio C. Wolff, Vered Stearns, Elizabeth M. Jaffee and Leisha A. Emens

  Cancer Immunol Res October 1 2014 2 (10) 949-961; DOI:10.1158/2326-6066.CIR-14-0058

  
  

  Chen and colleagues show in patients and in a mouse model of HER2⁺ breast cancer that abrogating immune suppression with low-dose cyclophosphamide along with administration of an allogeneic GM-CSF–secreting HER2⁺ tumor vaccine and trastuzumab weekly augmented HER2-specific T-cell responses and survival.
• Research Articles

  Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2⁺ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

  Nadine Norton, Rebecca M. Olson, Mark Pegram, Kathleen Tenner, Karla V. Ballman, Raphael Clynes, Keith L. Knutson and Edith A. Perez

  Cancer Immunol Res October 1 2014 2 (10) 962-969; DOI:10.1158/2326-6066.CIR-14-0059

  
  

  Norton, Olson, and colleagues found no differences in disease-free survival in trastuzumab-treated patients regardless of their FCGR2A and FCGR3A genotypes, but a significant difference between patients with FCGR2B variants, suggesting the functionality of FCGR2B may predict benefit to trastuzumab.
• Research Articles | AuthorChoice

  Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility

  Tsvetelina Pentcheva-Hoang, Tyler R. Simpson, Welby Montalvo-Ortiz and James P. Allison

  Cancer Immunol Res October 1 2014 2 (10) 970-980; DOI:10.1158/2326-6066.CIR-14-0104

  
  

  Pentcheva-Hoang and colleagues analyzed melanoma-specific T-cell dynamics in tumors and tumor-draining lymph nodes before and after immune checkpoint blockade, and their study demonstrates that successful immunotherapy correlates with greater T-cell motility and reversal of the T-cell paralysis in growing tumors.
• Research Articles

  Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival

  William E. Carson III, Joseph M. Unger, Jeffrey A. Sosman, Lawrence E. Flaherty, Ralph J. Tuthill, Mark J. Porter, John A. Thompson, Raymond A. Kempf, Megan Othus, Antoni Ribas and Vernon K. Sondak

  Cancer Immunol Res October 1 2014 2 (10) 981-987; DOI:10.1158/2326-6066.CIR-14-0052

  
  

  A final report of trial S9035 by Carson and colleagues indicates a significant overall benefit from the lysed adjuvant vaccine melacrine for patients with stage II to IV melanoma with HLA A2 and/or HLA Cw3 serotypes, implicating interactions between HLA haplotype and clinical outcome.
• Research Articles

  A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

  Douglas G. McNeel, Thomas A. Gardner, Celestia S. Higano, Philip W. Kantoff, Eric J. Small, Mark H. Wener, Robert B. Sims, Todd DeVries, Nadeem A. Sheikh and Robert Dreicer

  Cancer Immunol Res October 1 2014 2 (10) 988-999; DOI:10.1158/2326-6066.CIR-14-0073

  
  

  McNeel and colleagues demonstrate that a transient increase in eosinophil counts following sipuleucel-T treatment was associated with therapy-induced immune responses and longer prostate cancer survival, suggesting this could be prospectively evaluated as a biomarker in clinical trials.
• Research Articles

  Phenotypic and Functional Activation of Hyporesponsive KIR^negNKG2A^neg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells

  Shane A. Curran, Emanuela Romano, Michael G. Kennedy, Katharine C. Hsu and James W. Young

  Cancer Immunol Res October 1 2014 2 (10) 1000-1010; DOI:10.1158/2326-6066.CIR-14-0054-T

  
  

  Curran and colleagues show that IL12p70 from human DCs induces NK-cell precursors to transition from KIR/NKG2A-negative to positive and become functionally active, providing a rationale for generating donor NK cells against missing KIR ligands to enhance the graft-versus-leukemia effect after allogeneic HSCT.
• Research Articles

  TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models

  Kristina H. Young, Pippa Newell, Benjamin Cottam, David Friedman, Talicia Savage, Jason R. Baird, Emmanuel Akporiaye, Michael J. Gough and Marka Crittenden

  Cancer Immunol Res October 1 2014 2 (10) 1011-1022; DOI:10.1158/2326-6066.CIR-13-0207

  
  

  Young and colleagues demonstrate in syngeneic mouse models of colorectal and pancreatic cancers that TGFβ inhibition with the oral, small-molecule inhibitor SM16 enhanced adaptive immunity in the tumor microenvironments and significantly improved the efficacy of subsequent radiotherapy.